Next 10 |
2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...
2024-04-05 18:30:02 ET Stephens analyst issues BUY recommendation for NTRA on April 5, 2024 05:00PM ET. The previous analyst recommendation was Buy. NTRA was trading at $96.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...
Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $95.17. So far today, approximately 361.85k shares have been exchanged, as compared to an average 30-day volume of 1.38M shares. Natera, Inc., a diagnostics company, develops and commercializ...
2024-04-05 10:00:07 ET Read the full article on Seeking Alpha For further details see: Natera upgraded at Bernstein on gross margin trajectory
Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 ...
News, Short Squeeze, Breakout and More Instantly...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...